Pulse Biosciences (PLSE) Net Income towards Common Stockholders (2015 - 2025)

Pulse Biosciences' Net Income towards Common Stockholders history runs 11 years deep, the most recent figure standing at -$19.4 million for Q3 2025.

• In Q3 2025, Net Income towards Common Stockholders fell 52.73% year-over-year to -$19.4 million; the TTM figure through Dec 2025 stood at -$55.3 million (down 203.23% YoY), while the FY2025 annual figure was $72.8 million, up 35.82% from the prior year.
• Net Income towards Common Stockholders was -$19.4 million for Q3 2025 at Pulse Biosciences, down from -$19.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $87.8 million in Q4 2024 to a low of -$19.4 million in Q3 2025.
• Historically, Net Income towards Common Stockholders has averaged -$8.8 million across 5 years, with a median of -$14.0 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders surged 835.77% in 2024, then plunged 68.39% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$15.4 million in 2021, then surged by 40.34% to -$9.2 million in 2022, then retreated by 29.75% to -$11.9 million in 2023, then soared by 835.77% to $87.8 million in 2024, then sank by 122.06% to -$19.4 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$19.4 million (Q3 2025), -$19.2 million (Q2 2025), and -$16.8 million (Q1 2025), per Business Quant data.